Updated
- Log In
- Newsletters
-
Subscribe
Access insights and guidance from our Wall Street pros. Find the product that's right for you.
Pharmaceuticals
Teva Notches Win With FDA Approval of Generic EpiPen
The regulatory agency has authorized the sale of the drugmaker's generic version of Mylan's EpiPen.
Opioid Makers Continue to Rise in Spite of Potential Trump-Directed Lawsuits
Insys Therapeutics, Cardinal Health and McKesson are just some of the public companies that could be affected by the Trump administration directive.
Buffett Ups Stake in Teva
Warren Buffett's Berkshire Hathaway increases its stake in the drugmaker to 43.2 million shares from 40.5 million shares at the end of March.
Amgen: Cramer Discusses the AAP Portfolio's New Edition
In the August Action Alerts PLUS members' call, Jim Cramer and Jeff Marks, Senior Portfolio Analyst of Action Alerts PLUS, discuss the portfolio's new edition of Amgen.
3 Cheap Healthcare Stocks That Won't Make Your Portfolio Sick
The healthcare space continues to be ripe for investment opportunity. Here are three stocks that won't make your portfolio sick.
Tesla Take Private Deal Takes Backseat to 2 Fresh Overseas Crises: Week Ahead
The market rally will start the week on shaky footing after a tough selloff Friday amid Turkey's currency crisis. Will Tesla get sold this week?
Jim Cramer: Rite Aid Doesn't Have the Balance Sheet to Be Independent
They pulled the plus on the Rite Aid-Alberstons merger ahead of the vote -- listen to Cramer react to that now!
This Company Is at the Center of Insider Trading Charges Against Rep. Collins
Innate Immunotherapeutics of Australia is the biopharmaceutical company at the center of the insider trading charges leveled against New York Rep. Chris Collins.
Rite Aid Gets Rocked After Cutting Drug Purchasing Efficiencies
Rite Aid's generic drug purchasing power is likely much lower than previously forecast. What does this mean for CVS? Here are some answers.
Why Investors Should Favor Smaller Biotech Companies
Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.